All categories
Intermediates
- Categories:在售产品
- Time of issue:2020-12-09 19:20:33
- Views:0
Description:
Information
Intermediates Product List
| API Category | Chemical Name | CAS No. | Production Stage | Factory Condition | |
| Lacosamide | (R)-2-Amino-N-Benzyl-3-Methoxypropanamide | 196601-69-1 | Commercial | FDA/GMP | |
| (R)-Tert-Butyl 1-(Benzylamino)-3-Methoxy-1-Oxopropan-2- Ylcarbamate | 880468-89-3 | Commercial | FDA/GMP | ||
| Agomelatine | 7-Methoxy-1-Naphthyl-Acetonitrile | 138113-08-3 | Commercial | GMP | |
| 7-Methoxy-1-Tetralone | 6836-19-7 | Commercial | GMP | ||
| Pirfenidone | 5-Methyl-2-Pyridone | 1003-68-5 | Commercial | GMP | |
| Tianeptine Sodium | Tianeptine Acid | 66981-73-5 | Commercial | GMP | |
| 3-Chloro-6-methyl-dibenzo[c,f][1,2]thiazepin-11(6H)-one 5,5-dioxide | 26638-53-9 | Commercial | GMP | ||
| 3-Chloro-6,11-Dihydro-6-Methyldibenzo[c,f][1,2]Thiazepin-11-ol 5,5-Dioxide | 26723-60-4 | Commercial | GMP | ||
| 3,11-Dichloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepine 5,5-dioxide | 26638-66-4 | Commercial | GMP | ||
| Lenalidomide | Methyl 2-Methyl-3-Nitrobenzoate | 59382-59-1 | Commercial | GMP | |
| Methyl 2-Bromomethyl-3-Nitrobenzoate | 98475-07-1 | Commercial | GMP | ||
| 3-Amino-2,6-Piperidinedione Hydrochloride | 24666-56-6 | Commercial | GMP | ||
| 3-(4-Nitro-1-Oxoisoindolin-2-Yl)Piperidin-2,6-Dione | 827026-45-9 | Commercial | GMP | ||
| Prasugrel HCL | 5,6,7,7A-Tetrahydrothieno[3,2-C]Pyridine-2(4H)-One Hydrochloride | 115473-15-9 | Commercial | FDA/GMP | |
| 2-Bromo-2-(2-Fluorophenyl)-1-Cyclopropylethanone | 204205-33-4 | Commercial | FDA/GMP | ||
| Cyclopropyl-2-(2-Fluorophenyl)Ethan-1-One | 150322-73-9 | Commercial | FDA/GMP | ||
| Pitavastatin Calcium | Tert-Butyl (4R-Cis)-6-Formaldehydel-2,2-Dimethyl-1,3-Dioxane-4-Acetate | 124752-23-4 | Commercial | FDA/GMP | |
| [[2-Cyclopropyl-4-(4-Fluorophenyl)-3-Quinolinyl]Methyl]Triphenylphosphonium Bromide | 154057-58-6 | Commercial | FDA/GMP | ||
| (4R,6S)-6-[(1E)-2-[2-Cyclopropyl-4-(4-Fluorophenyl)-3-Quinolinyl]Ethenyl]-2,2-Dimethyl-1,3-Dioxane-4-Acetic Acid Tert-Butyl Ester | 147489-06-3 | Commercial | FDA/GMP | ||
| Ambrisentan | S)-(+)-2-Phenylglycine amide | 6485-52-5 | Commercial | FDA/GMP | |
| 2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid | 178306-51-9 | Commercial | FDA/GMP | ||
| (S)-2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid | 178306-52-0 | Commercial | FDA/GMP | ||
| 2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid Methyl Ester | 178306-47-3 | Commercial | FDA/GMP | ||
| Isavuconazonium Sulfate | 2-(Methylamino)Pyridine-3-Methanol | 32399-12-5 | Commercial | FDA/GMP | |
| 4-(2-Bromoacetyl)Benzonitrile | 20099-89-2 | Commercial | FDA/GMP | ||
| (2R,3R)-3-(2,5-Difluorophenyl)-3-Hydroxy-2-Methyl-4-(1H-1,2,4-Triazol-1-Yl)Thiobutyramide | 368421-58-3 | Commercial | FDA/GMP | ||
| 1-(2,5-Difluorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethanone | 1157938-97-0 | Commercial | FDA/GMP | ||
| (2R,3R)-3-(2,5-Difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4-triazol-1-yl)butanoic acid | 483340-19-8 | Commercial | FDA/GMP | ||
| (2R,3R)-3-(2,5-Difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4-triazol-1-yl)butanamide | 241479-75-4 | Commercial | FDA/GMP | ||
| (2S,3R)-3-(2,5-Difluorophenyl)-3-Hydroxy-2-Methyl-4-(1H-1,2,4-Triazol-1-Yl)Butanenitrile | 241479-74-3 | Commercial | FDA/GMP | ||
| 2-(Methylamino)Pyridin-3-Yl)Methyl 2-((Tert-Butoxycarbonyl)(Methyl)Amino)Acetate | 1180002-01-0 | Commercial | FDA/GMP | ||
| N-[(1,1-Dimethylethoxy)Carbonyl]-N-Methyl-, [2-[[(1-Chloroethoxy)Carbonyl]Methylamino]-3-Pyridinyl]Methyl Ester | 338990-31-1 | Commercial | FDA/GMP | ||
| 4-[2-[(1R,2R)-2-(2,5-Difluorophenyl)-2-Hydroxy-1-Methyl-3-(1H-1,2,4-Triazol-1-Yl)Propyl]-4-Thiazolyl]Benzonitrile | 241479-67-4 | Commercial | FDA/GMP | ||
| Tigecycline | N-Tert-Butylglycine Hcl | 6939-23-7 | Commercial | FDA/GMP | |
| 9-Amino Minocycline Hcl | 149934-21-4 | Commercial | FDA/GMP | ||
| 9-Amino Minocycline Sulfate | 149934-20-3 | Commercial | FDA/GMP | ||
| Minodronic Acid | Imidazo[1,2-A]Pyridin-3-Yl-Acetic Acid | 17745-04-9 | Commercial | FDA/GMP | |
| Ethyl Trans-4-Oxo-2-Butenoate | 2960-66-9 | Commercial | FDA/GMP | ||
| Bempedoic Acid | Diethyl 2,2,14,14-tetramethyl-8-oxopentadecanedioate | 738606-43-4 | Commercial | FDA/GMP | |
| 2,2,14,14-tetramethyl-8-oxopentadecanedioic Acid | 413624-71-2 | Commercial | FDA/GMP | ||
| Cenobamate | 2-Bromo-2'-Chloroacetophenone | 5000-66-8 | Commercial | FDA/GMP | |
| 1-(2-Chlorophenyl)-2-(1,2,3,4-Tetrazol-2-Yl)Ethan-1-One | 1259059-71-6 | Commercial | FDA/GMP | ||
| Tedizolid Phosphate | Carbamic Acid, N-[3-fluoro-4-[6-(2-methyl-2h-tetrazol-5-yl)-3-pyridinyl]phenyl]-, Phenylmethyl Ester | 1220910-89-3 | Pilot | FDA/GMP | |
| Tofacitinib citrate | (3R,4R)-1-Benzyl-N,4-dimethyl-3-piperidinamine | 477600-70-7 | Pilot | FDA/GMP | |
| 6-Chloro-7-deazapurine | 3680-69-1 | Pilot | FDA/GMP | ||
| Fludarabine Phosphate | 2-Fluoroadenine | 700-49-2 | Commercial | FDA/GMP | |
| Osimertinib | 4-Fluoro-2-Methoxy-5-Nitroaniline | 1075705-01-9 | Pilot | FDA/GMP | |
| Atomoxetine | N,N-Dimethyl-3-(2-methylphenoxy)-3-phenyl-1-propanamine | 83015-25-2 | Pilot | FDA/GMP | |
| Relugolix | 6-Methoxypyridazin-3-Amine | 7252-84-8 | Pilot | FDA/GMP | |
| 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-nitrophenyl)thiophene-3 | 1589503-95-6 | Pilot | FDA/GMP | ||
| Ethyl (2,6-difluorobenzyl)(4-((dimethylamino)methyl)-3-((6-methoxypyridazin-3-yl)carbamoyl)-5-(4-nitrophenyl)thiophen-2-yl)carbamate | 1589503-94-5 | Pilot | FDA/GMP | ||
| Relugolix | 1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxy-3-pyridazinyl)-6-(4-nitrophenyl)-thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione,hydrochloride (1:1) | 1589503-99-0 | Pilot | FDA/GMP | |
| 6-(4-Aminophenyl)-1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione | 1589503-93-4 | Pilot | FDA/GMP | ||
| Others | 3-Aminobenzoic Acid | 99-05-8 | Commercial | GMP | |
| 2,2'-Anhydro-1-Beta-D-Arabinofuranosylcytosine Hydrochloride | 10212-25-6 | Commercial | GMP | ||
| 2,4-Di-Tert-Butyl-5-Nitrophenyl Methyl Carbonate | 873055-55-1 | Commercial | GMP | ||
| 6-Chloro-4-methylpyridazin-3-amine | 64068-00-4 | Commercial | GMP | ||
| Ethyl 7-chloro-2-oxoheptanoate | 78834-75-0 | Commercial | GMP | ||
| 4-Chlorophenylhydrazine | 1073-69-4 | Commercial | GMP | ||
| 4-Chlorophenylhydrazine hydrochloride | 1073-70-7 | Commercial | GMP | ||
| 5-Methyl-2-pyrazinecarboxylic acid | 5521-55-1 | Commercial | GMP | ||
| 5-Cyanophthalide | 82104-74-3 | Commercial | GMP | ||
| N,N'-Diemthyl-N-Methyllisonipecotamide | 613678-09-4 | Commercial | GMP | ||
| 6,6-DiMethyl-3-azabicyclo[3.1.0]hexane Boceprevir Key interMediate | 943516-54-9 | Commercial | GMP | ||
| (2-Chloro-3-Pyridinyl)Methanol | 42330-59-6 | Commercial | GMP | ||
Under Development
| API Category | Chemical Name | CAS No. | Production Stage | Factory Condition | |
| Ibrutinib | 5-(4-Phenoxyphenyl)-7H-Pyrrolo[2,3-D]Pyrimidin-4-Ylamine | 330786-24-8 | Lab Scale | FDA/GMP | |
| 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile | 330792-70-6 | Lab Scale | FDA/GMP | ||
| (R)-tert-Butyl 3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate (N-1) | 1022150-11-3 | Lab Scale | FDA/GMP | ||
| (R)-3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyriMidin-4-aMine | 1022150-12-4 | Lab Scale | FDA/GMP | ||
| Elagolix Sodium | 2-fluoro-3-methoxyphenylboronic Acid | 352303-67-4 | Lab Scale | FDA/GMP | |
| Apalutamide | 1-Amino-N-[6-Cyano-5-(Trifluoromethyl)-3-Pyridinyl]Cyclobutanecarboxamide | 1950587-17-3 | Lab Scale | FDA/GMP | |
| 4-((1-((6-Cyano-5-(Trifluoromethyl)Pyridin-3-Yl)Carbamoyl)Cyclobutyl)Amino)-2-Fluoro-N-Methylbenzamide | 1950587-20-8 | Lab Scale | FDA/GMP | ||
| Olaparib | 2-Fluoro-5-[(3-Oxo-1(3H)-Isobenzofuranylidene)Methyl]-Benzonitrile | 763114-25-6 | Lab Scale | FDA/GMP | |
| 2-Fluoro-5-((4-Oxo-3,4-Dihydrophthalazin-1-Yl)Methyl)Benzonitrile | 1021298-68-9 | Lab Scale | FDA/GMP | ||
| 2-Fluoro-5-((4-Oxo-3,4-Dihydrophthalazin-1-Yl)Methyl)Benzoic Acid | 763114-26-7 | Lab Scale | FDA/GMP | ||
| Filgotinib | 5-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine | 1010120-55-4 | Lab Scale | FDA/GMP | |
| 2-Pyridinamine, 6-(4-methylphenyl)-, hydrochloride (1:1) | 1233697-39-6 | Lab Scale | FDA/GMP | ||
| cyclopropanecarboxylic acid (5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-amide | 1142943-96-1 | Lab Scale | FDA/GMP | ||
| 4-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzyl]thiomorpholine 1,1-dioxide | 1092563-25-1 | Lab Scale | FDA/GMP | ||
| Cyclopropanecarboxamide, N-[5-(4-methylphenyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]- | 1142936-90-0 | Lab Scale | FDA/GMP | ||
| N-(5-(4-(bromomethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide | 1206163-59-8 | Lab Scale | FDA/GMP | ||
| Beraprost sodium | 1H-Cyclopenta[b]benzofuran-5-butanoic acid, 2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-formyl-2,3,3a,8b-tetrahydro-, methyl ester, (1R,2R,3aS,8bS)- | 1416129-69-5 | Lab Scale | FDA/GMP | |
| Phosphonic acid,(3-methyl-2-oxo-5-heptynyl)-, dimethyl ester | 70073-58-4 | Lab Scale | FDA/GMP | ||
| Upadacitinib | Tert-Butyl 5-Tosyl-5H-Pyrrolo[2,3-B]Pyrazin-2-Ylcarbamate | 1201187-44-1 | Lab Scale | FDA/GMP | |
| Benzyl (3R,4S)-3-(bromoacetyl)-4-ethyl-1-Pyrrolidinecarboxylate | 1428243-26-8 | Lab Scale | FDA/GMP | ||
| N-[5-[(4-Methylphenyl)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-2-yl]carbamic acid ethyl ester | 1869118-24-0 | Lab Scale | FDA/GMP | ||
| 3,5-Dibromopyrazin-2-amine | 24241-18-7 | Lab Scale | FDA/GMP | ||
Disclaimer:
- This list of products and reference to any product herein should not be construed and/or constituted transaction where it is not permitted underpatent law of the country and/or
is not authorized by other laws and regulations of the country. - All the products under the patent are only for R&D use.
Beijing Hope Pharmaceutical Co., Ltd. 京ICP备17065299号
